| Literature DB >> 33061279 |
Kavin Vanikieti1, Pavarut Janyaprasert1, Sirin Lueangram1, Jirat Nimworaphan1, Natthapon Rattanathamsakul1, Nanida Tiraset1, Wimonwan Chokthaweesak1, Narong Samipak1, Tanyatuth Padungkiatsagul1, Pisit Preechawat1, Anuchit Poonyathalang1, Teeratorn Pulkes2, Supoch Tunlayadechanont2, Sukanya Siriyotha3, Panitha Jindahra2.
Abstract
PURPOSE: To analyze the demographic patterns, clinical characteristics and etiologies of acute optic neuritis (ON).Entities:
Keywords: autoimmune disorders; multiple sclerosis; myelin oligodendrocyte glycoprotein antibody-associated disorder; neuromyelitis optica spectrum disorder; optic neuritis; postinfection
Year: 2020 PMID: 33061279 PMCID: PMC7533266 DOI: 10.2147/OPTH.S271820
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Figure 1Pie-chart showing the frequencies of etiologies of acute optic neuritis.
Patients’ Demographics, Grouped by Diagnosis
| Factors | MS n=3 (Patients) | NMOSD n=53 | MOG n=9 | Other Autoimmune Disorder n=17 | Postinfection n=1 | Idiopathic n=88 | All Group Analysis P value | Subgroup Analysis* P value |
|---|---|---|---|---|---|---|---|---|
| Sex, n (%) | ||||||||
| Female | 2 (66.7) | 49 (92.5) | 5 (55.6) | 13 (76.5) | 1 (100.0) | 64 (72.7) | 0.02 | 0.009 |
| Male | 1 (33.3) | 4 (7.5) | 4 (44.4) | 4 (23.5) | 0 (0.0) | 24 (27.3) | ||
| Age, mean (SD) | 31.7 (6.4) | 43.2 (16.0) | 46.1 (18.1) | 47.1 (12.2) | 29 (0.0) | 46.2 (15.5) | 0.42 | 0.41 |
| Initial VA, median (range) | 0.6 (0.1, 0.6) | 2.6 (0.7, 2.7) | 0.9 (0.7, 2.6) | 1.2 (0.3, 2.6) | 2.6 (2.6, 2.6) | 2.6 (0.8, 2.7) | 0.30 | 0.07 |
| Race, n (%) | ||||||||
| Thai | 2 (66.7) | 52 (98.1) | 9 (100.0) | 17 (100.0) | 1 (100.0) | 88 (100.0) | 0.04 | 0.11 |
| Caucasian | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Asian | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Pain, n (%) | ||||||||
| Present | 2 (66.7) | 31 (58.5) | 7 (77.8) | 6 (35.3) | 1 (100.0) | 41 (46.6) | 0.17 | 0.68 |
| Absent | 1 (33.3) | 22 (41.5) | 2 (22.2) | 11 (64.7) | 0 (0.0) | 47 (53.4) | ||
| Bilaterality, n (%) | ||||||||
| Single | 3 (100.0) | 40 (75.5) | 4 (44.4) | 8 (47.1) | 1 (100.0) | 60 (68.2) | 0.11 | 0.14 |
| Bilateral | 0 (0.0) | 13 (24.5) | 5 (55.6) | 9 (52.9) | 0 (0.0) | 28 (31.8) | ||
| Disc, eyes (%) | ||||||||
| Normal | 1 (33.3) | 35 (53.0) | 1 (7.1) | 19 (73.1) | 1 (100.0) | 53 (45.7) | <0.001 | <0.001 |
| Swelling | 1 (33.3) | 12 (18.2) | 11 (78.6) | 6 (23.1) | 0 (0.0) | 43 (37.1) | ||
| Pale | 1 (33.3) | 19 (28.8) | 2 (14.3) | 1 (3.8) | 0 (0.0) | 20 (17.2) |
Note: *Subgroup analysis (MS, NMOSD, and MOG).
Abbreviations: MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; MOG, myelin oligodendrocyte glycoprotein antibody; VA, visual acuity; SD, standard deviation; logMAR, log minimum angle of resolution.
Frequency of Enhanced Optic Nerves on Contrast-Enhanced T1-Weighted Orbital Magnetic Resonance Imaging with Fat Suppression in Different Segments of the Optic Nerve
| Segments of the Optic Nerve | MS n=3 (eyes) | NMOSD n=66 | MOG n=14 | Other Autoimmune Disorders n=26 | Postinfection n=1 | Idiopathic n=116 | All Group Analysis P value | Subgroup Analysis* P value |
|---|---|---|---|---|---|---|---|---|
| Intraorbital, n (%) | 2 (66.7) | 34 (51.5) | 12 (85.7) | 12 (46.2) | 1 (100.0) | 70 (60.3) | 0.17 | 0.18 |
| Intracanal, n (%) | 3 (100.0) | 37 (56.1) | 11 (78.6) | 16 (61.5) | 1 (100.0) | 71 (61.2) | 0.78 | 0.30 |
| Intracranial, n (%) | 0 (0.0) | 23 (34.8) | 5 (35.7) | 10 (38.5) | 0 (0.0) | 41 (35.3) | 0.89 | 0.53 |
| Chiasm, n (%) | 0 (0.0) | 9 (13.6) | 2 (14.3) | 2 (7.7) | 0 (0.0) | 14 (12) | 0.88 | 1.00 |
| Tract, n (%) | 0 (0.0) | 6 (9.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (4.3) | 0.36 | 0.68 |
Note: *Subgroup analysis (MS, NMOSD, and MOG).
Abbreviations: MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; MOG, myelin oligodendrocyte glycoprotein antibody.
Figure 2Fat-suppressed T1-weighted magnetic resonance imaging of the orbits with contrast shows (A) right optic nerve enhancement at the intraorbital segment in a patient with MS; (B) right optic nerve enhancement from the intraorbital segment to the intracranial segment in a patient with NMOSD; (C) bilateral optic nerve enhancement at the intraorbital and intracanal segments with optic nerve sheath and peribulbar fat involvement in a patient with MOGAD; (D) bilateral optic nerve involvement in a patient with CRION and anti-Jo1; and (E) mild enhancement of the perioptic nerve sheath complex at the intracanalicular segment of the left optic nerve in a patient with RION and idiopathic ON.